Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:1613-1617

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vink, A.
Right arrow Articles by Pasterkamp, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vink, A.
Right arrow Articles by Pasterkamp, G.
Related Collections
Right arrow Peripheral vascular disease
Right arrow Other etiology
Right arrow Pathophysiology

(Circulation. 2001;103:1613.)
© 2001 American Heart Association, Inc.


Clinical Investigation and Reports

Distribution of Chlamydia pneumoniae in the Human Arterial System and Its Relation to the Local Amount of Atherosclerosis Within the Individual

Aryan Vink, MD; Marieke Poppen; Arjan H. Schoneveld, BSc; Paul J. M. Roholl, PhD; Dominique P. V. de Kleijn, PhD; Cornelius Borst, MD, PhD; Gerard Pasterkamp, MD, PhD

From the Department of Cardiology, University Medical Center Utrecht (A.V., G.P., M.P., A.H.S., D.P.V. de K., C.B.), and Interuniversity Cardiology Institute of the Netherlands (A.V., G.P., M.P., A.H.S., D.P.V. de K.), Utrecht, and Laboratory for Pathology and Immunobiology, National Institute of Public Health and the Environment (P.J.M.R.), Bilthoven, The Netherlands.

Correspondence to Gerard Pasterkamp, MD, PhD, University Medical Center Utrecht, Experimental Cardiology Laboratory, Room G02-523, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. E-mail g.pasterkamp{at}hli.azu.nl


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
BackgroundChlamydia pneumoniae has been suggested to play a role in the origin of atherosclerosis. We studied the prevalence of C pneumoniae at multiple locations in the arterial system within the same individual. Studying the association between atherosclerosis and C pneumoniae within the individual excludes confounding by interindividual variability.

Methods and Results—Postmortem, the presence in the intima/plaque and media of C pneumoniae membrane protein was determined by use of a C pneumoniae–specific monoclonal antibody. In 24 individuals, 33 arterial locations were studied (n=738 segments). Area stenosis was determined in adjacent cross sections. In all individuals, immunostaining of C pneumoniae was observed in >=1 artery. The highest prevalences were observed in the abdominal aorta (67%), internal and common iliac arteries (41%), and coronary arteries (33%). The lowest prevalences were observed in the radial (0%) and cerebral (2%) arteries. Within the individual, area stenosis was larger in cross sections with immunoreactivity compared with cross sections without immunoreactivity (31.0±11.9% versus 14.3±6.1%, respectively; P<0.001). In the individual, immunoreactivity was observed in 15±10% of the arteries (range, 3% to 45%). Between individuals, the percentage of arteries with immunoreactivity to C pneumoniae was associated with the average area stenosis throughout the arterial system (r2=0.56, P<0.001).

ConclusionsC pneumoniae was mostly observed at locations that are related to clinically relevant features. Within the individual, the distribution of C pneumoniae is associated with the distribution of atherosclerosis. The role of the microorganism in atherosclerotic disease remains to be elucidated.


Key Words: atherosclerosis • Chlamydia pneumoniae • pathology


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Chlamydia pneumoniae is a Gram-negative obligate intracellular bacterium that is a common cause of respiratory disease.1 Infection with C pneumoniae seems to be geographically widespread, and a high population prevalence of antibodies against the microorganism has been found, suggesting that most people are infected.2 3

Increasing evidence exists that C pneumoniae might play a role in atherosclerotic disease. An association between the microorganism and atherosclerosis was first demonstrated in seroepidemiological studies.4 5 In addition, C pneumoniae has been detected in human atherosclerotic lesions by various techniques like polymerase chain reaction, immunohistochemistry, electron microscopy, and culture.6 Thus far, the presence of the microorganism has been studied in only 1 or a small number of arterial locations within the same individual. In addition, negative control samples without atherosclerosis were obtained from different individuals who were mostly not age matched. Concern about these controls has been expressed by others.6 Within the individual, the distribution pattern of C pneumoniae has not been described.

Studying the localization of C pneumoniae within individuals is the most appropriate method to study the relation between local plaque formation and the presence of C pneumoniae, thereby excluding interindividual variability. In 24 individuals, we studied the presence of C pneumoniae at 33 different arterial locations with and without atherosclerotic disease. The aims of the present study were to determine the distribution pattern of C pneumoniae in the human arterial tree and to study whether within the individual this distribution pattern is associated with the distribution of atherosclerosis.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Postmortem, 24 donated corpses (11 men and 13 women; age, 81.9±9.9 years; history of cardiovascular risk factors unknown) were pressure fixed with 4% formalin in situ (pressure, age+100 mm Hg). In each corpse, arterial segments were dissected at 33 different locations: left and right (L+R) anterior, medial, and posterior cerebral arteries; basilar artery; common and internal carotid arteries (L+R); brachial arteries (L+R); radial arteries (L+R); ascending and abdominal aorta; pulmonary arteries (L+R); left anterior descending coronary artery; left circumflex coronary artery; right coronary artery; superior mesenteric artery; renal arteries (L+R); common, internal, and external iliac arteries (L+R); and femoral arteries (L+R). For each artery type, the location was standardized.

Of each artery, 1 paraffin section was stained for C pneumoniae–specific membrane protein. Sections were deparaffinized, and endogenous peroxidase was blocked with methanol containing 2% H2O2. Next, sections were pretreated with 0.5% blocking solution (Roche) and incubated with a monoclonal antibody directed against C pneumoniae–specific membrane protein7 (clone RR-402; Washington Research Foundation) in a concentration of 5 µg/mL. Biotinylated horse anti-mouse polyclonal antibody (Vector) was used as secondary antibody. For detection, sections were incubated with streptavidin–horseradish peroxidase followed by treatment with diaminobenzidine/nickel substrate. The sections were counterstained with Nuclear Fast Red (Merck). Adjacent sections were incubated with an irrelevant primary monoclonal antibody of the same isotype (mouse IgG3{lambda}, clone G19-143; Pharmingen). HEp2 cells (CCL23; American Type Culture Collection) infected with C pneumoniae strain TW-183 were used as positive control. Mock-infected HEp2 cells were used as negative control.

A cell was considered positive when cellular immunoreactivity was observed. Immunoreactivity in the intima/plaque and media was categorized according to the following 4 grades: 3+, immunoreactivity in >50 cells; 2+, immunoreactivity in 10 to 50 cells; 1+, immunoreactivity in 2 to 9 cells; and 0, no immunoreactivity.

To assess the local amount of atherosclerosis, adjacent sections were stained with Elastin-van Gieson stain. Microscopic images of the cross sections were recorded on VHS videotape with a 3CCD video camera. In each cross section, the lumen area, the area encompassed by the internal elastic lamina (IEL), and the circumference of the IEL were measured. Plaque area was calculated by subtracting the lumen area from the measured IEL area. To avoid any distortion of the IEL area by cutting, the corrected IEL area was calculated as follows: IEL area corrected=(circumference IEL)2/4{pi}. Area stenosis is a measure of the amount of plaque in a cross section corrected for arterial size and was calculated as follows: (plaque area/IEL area corrected)x100%.

Under physiological conditions, the pulmonary artery is exposed to a lower pressure than the other artery types. Therefore, it is unknown whether the mechanisms underlying the development of atherosclerosis are the same for the pulmonary artery and the other artery types. Consequently, the pulmonary artery was not included in the analysis in which cross sections of multiple locations were pooled.

Statistical Analysis
Student’s t test was used to compare area stenosis of cross sections with and without immunoreactivity. A paired t test was used to compare area stenosis of cross sections with and without immunoreactivity within individuals. Linear regression analysis was used to correlate the percentage of arteries with immunoreactivity with the average area stenosis of the individual. Values are presented as mean±SD. A value of P<0.05 was considered statistically significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
From 24 individuals, 766 arterial segments were harvested. Appropriate staining was available of 738 cross sections (30.8±1.7 per individual). The staining of 28 cross sections could not be interpreted because of background staining. In all 24 individuals, immunoreactivity to C pneumoniae–specific antigen was observed in >=1 artery. Immunoreactivity to C pneumoniae–specific antigen (Figure 1Down) was observed in 111 of 738 arterial segments (15%). In 64 of these 111 cross sections (58%), immunoreactivity was observed in <10 cells (the TableDown). In 77 cross sections, immunoreactivity was found in the plaque only; in 9 cross sections, in the media only; and in 25 cross sections, in both the plaque and media. Mock-infected HEp2 cells and sections incubated with the isotype antibody consistently showed no staining.



View larger version (84K):
[in this window]
[in a new window]
 
Figure 1. A, Cells with immunoreactivity to C pneumoniae–specific membrane protein in shoulder of plaque of internal iliac artery. B, Cells with immunoreactivity around microvessel in media of abdominal aorta. Magnification, 400x; bar=50 µm.


View this table:
[in this window]
[in a new window]
 
Table 1. Number of Arteries With Immunoreactivity to C pneumoniae Membrane Protein and Average Area Stenosis per Artery Type

The TableUp shows the number of arteries with immunoreactivity to C pneumoniae–specific antigen per artery type. The highest prevalences of immunoreactivity were found in the abdominal aorta, common and internal iliac arteries, and coronary arteries. Immunoreactivity was not observed in the radial artery and medial cerebral artery. Immunoreactivity was predominantly observed in artery types with the highest area stenosis (the TableUp). Pooling all cross sections of all individuals showed that area stenosis in cross sections with immunoreactivity was larger than in cross sections without immunoreactivity (Figure 2Down). Within the individual, area stenosis was larger in cross sections in which immunoreactivity was observed compared with cross sections without immunoreactivity (Figure 3ADown). Within the same individual, moreover, area stenosis was associated with the presence of immunoreactivity within the same artery type, eg, the coronary arteries. In 15 individuals, coronary immunoreactivity to C pneumoniae was observed in 1 or 2 of the 3 coronary arteries. In these individuals, area stenoses of C pneumoniae–positive and –negative coronary cross sections were compared. Comparison of the coronary arteries of the same individual revealed that area stenosis of cross sections with immunoreactivity was larger than that of nonstaining cross sections (Figure 3BDown).



View larger version (8K):
[in this window]
[in a new window]
 
Figure 2. Area stenosis (AS, %) of all pooled cross sections with (Cpmp+) and without (Cpmp-) immunoreactivity to C pneumoniae–specific membrane protein.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 3. A, Average area stenosis (AS, %) of cross sections with (Cpmp+) and without (Cpmp-) immunoreactivity to C pneumoniae–specific membrane protein for each individual. In each individual, average area stenoses in cross sections with and without immunoreactivity are connected by line. B, Same analysis in subgroup of 15 individuals in whom immunoreactivity to C pneumoniae was observed in 1 or 2 of 3 coronary arteries. In each individual, (average) area stenosis of C pneumoniae–positive and –negative coronary arteries are connected by line. Means and SD (bars) are shown for each group.

In the individual, immunoreactivity was observed in 15±10% of the studied arteries (range, 3% to 45%). Figure 4Down shows a histogram of the percentage of arteries with immunoreactivity per individual. The histogram indicates that there is wide variation between different individuals in the number of arteries in which C pneumoniae was detected. A significant correlation between the average area stenosis of all studied arteries of the individual and the percentage of arteries with immunoreactivity in that individual is shown in Figure 5Down (r2=0.56, P<0.001).



View larger version (10K):
[in this window]
[in a new window]
 
Figure 4. Histogram of number of individuals vs percentage of arteries with immunoreactivity to C pneumoniae membrane protein (Cpmp+) in each individual.



View larger version (10K):
[in this window]
[in a new window]
 
Figure 5. Association between average area stenosis (AS) of all studied arteries within individual and percentage of arteries positive for C pneumoniae membrane protein (Cpmp+) within individual. Plot of percentage of arteries positive for C pneumoniae membrane protein (Cpmp+) within the individual vs average area stenosis with regression line.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The respiratory pathogen C pneumoniae is assumed to disseminate from the lungs to vascular tissue.8 9 Evidence that the microorganism plays a role in atherosclerotic disease is growing.10 Thus far, all studies analyzing the presence of C pneumoniae in human atherosclerotic arteries focused on only 1 or a limited number of locations within a single individual. In most of these studies, negative controls without atherosclerotic disease were obtained from another group of individuals. As previously reported,6 most controls that were used were younger, raising the question of whether the difference in prevalence was due to the age of the subjects rather than the condition of the vessels. Also, other interindividual variables, like smoking status,11 12 merit careful consideration. In addition, only a selection of artery types, like the coronary arteries, aorta, and carotid artery, was studied in adequate numbers to obtain representative results for these artery types. This is the first study in which the presence of C pneumoniae was systematically studied throughout the arterial system and related to atherosclerotic disease within the same individual. Therefore, interindividual variation in factors that influence infection and dissemination of C pneumoniae is controlled for, because both atherosclerotic and nonatherosclerotic arteries are studied within the same individual.

Distribution in Arterial System
Our results indicate that within the individual C pneumoniae is widely disseminated in the arterial tree. To the best of our knowledge, this study adds the renal, superior mesenteric, basilar, and anterior and posterior cerebral arteries to the list of artery types in which the microorganism has been reported. Although the microorganism was widespread, it was not randomly distributed in the human arterial tree. Artery types in which the microorganism was highly prevalent included the abdominal aorta, coronary arteries, and common and internal iliac arteries, which are all known for their relation to clinically relevant atherosclerosis. Detection of C pneumoniae in these artery types is in accordance with previous findings.13 14 15 16 17 C pneumoniae seemed to be preferentially located in atherosclerotic arteries, because even within the arterial system of one individual, area stenosis was found to be associated with the presence of immunoreactivity to C pneumoniae (Figure 3Up). Moreover, within the same individual, area stenosis in the 3 coronary arteries was found to be positively associated with immunoreactivity for C pneumoniae, indicating that the association between atherosclerosis and the presence of the microorganism persists within the same artery type. In previous studies, C pneumoniae was preferentially found in atherosclerotic arteries compared with arteries without atherosclerotic disease obtained from different individuals.13 14 16 The results of the present study demonstrate that within a single individual, C pneumoniae was preferentially located in atherosclerotic arteries.

Variation Between Individuals
Little is known about interindividual differences in distribution of C pneumoniae in the arterial tree. Among individuals, a wide range (3% to 45%) in the percentage of arteries with immunoreactivity to C pneumoniae was observed. Figure 4Up suggests that dissemination of C pneumoniae is not an "all or nothing" phenomenon, because then all arteries would show C pneumoniae immunoreactivity in one individual, whereas in other individuals, immunoreactivity to C pneumoniae would be absent. Multiple factors could influence the distribution of the microorganism in the arterial tree and explain the observed variation between individuals. The "atherosclerotic status" of the individual seemed to be associated with the number of arteries in which C pneumoniae was observed, because the percentage of arteries with the microorganism present in an individual was found to be associated with the average area stenosis throughout the arterial system of the individual. Thus, the more atherosclerosis there was within the individual, the more arteries in which C pneumoniae was prevalent were seen.

Role in Atherosclerosis
Because of the cross-sectional design of this study, we are unable to determine whether C pneumoniae colonizes atherosclerotic plaque when it already exists or plays a role in the initiation of the plaque. Thus, although the present study adds further evidence on the tight junction between C pneumoniae and atherosclerosis, it does not answer the basic question of whether C pneumoniae plays a causative role in atherosclerosis. Within the coronary arteries of the same individual, however, we found a correlation between the amount of atherosclerotic disease and the presence of C pneumoniae. This is consistent with the results of a recent autopsy study18 in which samples were obtained from 60 individuals. C pneumoniae immunoperoxidase staining was detected in 80% of individuals with severe atherosclerosis and in 38% of individuals with mild atherosclerosis. In another recent study,19 no association was found between the Stary grading of the atherosclerotic lesion and the presence of C pneumoniae in the vessel wall, which seems to contradict our results. A difference in the techniques used to detect the microorganism might explain the different results. We detected a membrane protein of C pneumoniae by immunohistochemistry, whereas in the above-mentioned study, C pneumoniae DNA was detected by polymerase chain reaction. If C pneumoniae would only initiate atherosclerotic disease, an equal prevalence could be expected in plaques of all sizes. It might be possible that C pneumoniae also has a role in the progression of the atherosclerotic process. Progression of the atherosclerotic lesion by C pneumoniae infection has been shown in rabbit20 and murine21 models.

Study Limitations
Only a 4-µm-thick slice of each artery was studied. This single sample likely gives an underestimation of the presence of the microorganism in the total artery. We used immunohistochemistry to detect C pneumoniae in arterial tissue. The monoclonal antibody used is directed against a membrane protein of C pneumoniae. Presence of the membrane protein does not necessarily reflect the presence of viable C pneumoniae. The postmortem material used was obtained from elderly individuals. Therefore, any reference to onset of atherosclerotic disease is unreliable. Because of this advanced age, one may also doubt reference to progression of atherosclerotic disease. However, a previous postmortem study revealed that plaques obtained from elderly individuals (>80 years) showed a comparable staining for inflammatory cells as plaques obtained from younger individuals.22

Conclusions
C pneumoniae was preferentially located in artery types that are associated with clinically relevant atherosclerosis. Within a single individual, the distribution of C pneumoniae was associated with the distribution of atherosclerosis. Between individuals, a wide variation in the presence of C pneumoniae in the arterial system was observed. However, it should be emphasized that although these results add further evidence of the association between C pneumoniae and atherosclerosis, they do not prove a causative or pathogenic role for the microorganism in atherosclerosis.


*    Acknowledgments
 
This study was supported by the Sorbo Foundation. Dr Pasterkamp is a fellow of the Catharijne Foundation, Utrecht. We gratefully thank W.J.A. van Wolveren and S. Plomp, Department of Functional Anatomy, University Medical Center Utrecht, for technical assistance.

Received October 11, 2000; revision received December 1, 2000; accepted December 9, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;161:618–625.[Medline] [Order article via Infotrieve]
  2. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. J Infect Dis. 1992;15:757–763.
  3. O’Neill C, Murray LJ, Ong GML, et al. Epidemiology of Chlamydia pneumoniae infection in a randomly selected population in a developed country. Epidemiol Infect. 1999;122:111–116.[Medline] [Order article via Infotrieve]
  4. Saikku P, Leinonen M, Matilla K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986.[Medline] [Order article via Infotrieve]
  5. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430–436.[Medline] [Order article via Infotrieve]
  6. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies. J Clin Pathol. 1998;51:793–797.[Medline] [Order article via Infotrieve]
  7. Puolakkainen M, Parker J, Kuo CC, et al. Further characterization of Chlamydia pneumoniae specific monoclonal antibodies. Microbiol Immunol. 1995;39:551–554.[Medline] [Order article via Infotrieve]
  8. Yang ZP, Kuo CC, Grayston JT. Systemic dissemination of Chlamydia pneumoniae following intranasal inoculation in mice. J Infect Dis. 1995;171:736–738.[Medline] [Order article via Infotrieve]
  9. Moazed TC, Kuo CC, Grayston JT, et al. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis. 1997;175:883–890.[Medline] [Order article via Infotrieve]
  10. Saikku P. Chlamydia pneumoniae in atherosclerosis. J Intern Med. 2000;247:391–396.[Medline] [Order article via Infotrieve]
  11. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae–coronary artery disease association. Arterioscler Thromb. 1992;12:945–947.[Abstract]
  12. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J. 1999;138:S504–S506.[Medline] [Order article via Infotrieve]
  13. Kuo CC, Gown AM, Benditt EP, et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501–1504.[Abstract]
  14. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J. 1992;82:158–61.[Medline] [Order article via Infotrieve]
  15. Campbell LA, O’Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 1995;172:585–8.[Medline] [Order article via Infotrieve]
  16. Ramirez JA, for the Chlamydia pneumoniae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 1996;125:979–982.[Abstract/Free Full Text]
  17. Ong G, Thomas BJ, Mansfield AO, et al. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol. 1996;49:102–106.[Abstract/Free Full Text]
  18. Ericson K, Saldeen TGP, Lindquist O, et al. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation. 2000;101:2568–2571.[Medline] [Order article via Infotrieve]
  19. Thomas M, Wong Y, Thomas D, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation. 1999;99:2733–2736.[Medline] [Order article via Infotrieve]
  20. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633–636.[Medline] [Order article via Infotrieve]
  21. Moazed TC, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis. 1999;180:238–241.[Medline] [Order article via Infotrieve]
  22. Pasterkamp G, Schoneveld AH, van der Wal AC, et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol. 1999;19:54–58.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
StrokeHome page
M. S.V. Elkind, M. L. C. Tondella, D. R. Feikin, B. S. Fields, S. Homma, and M. R. Di Tullio
Seropositivity to Chlamydia pneumoniae Is Associated With Risk of First Ischemic Stroke
Stroke, March 1, 2006; 37(3): 790 - 795.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
E Toubi and Y Shoenfeld
Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality?
Lupus, September 1, 2005; 14(9): 665 - 669.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. M. Miller, G. Rodgers, J. A. Charlesworth, B. Kirkland, S. R. Severson, T. E. Rasmussen, M. Yagubyan, J. C. Rodgers, F. R. Cockerill III, R. L. Folk, et al.
Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1115 - H1124.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
B. Ludewig, P. Krebs, and E. Scandella
Immunopathogenesis of atherosclerosis
J. Leukoc. Biol., August 1, 2004; 76(2): 300 - 306.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Baboonian, D. A Smith, D. Shapland, G. Arno, B. Zal, J. Akiyu, and J. C. Kaski
Placental infection with Chlamydia pneumoniae and intrauterine growth restriction
Cardiovasc Res, October 15, 2003; 60(1): 165 - 169.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S Cagli, N Oktar, T Dalbasti, S Erensoy, N Ozdamar, S Goksel, A Sayiner, and A Bilgic
Failure to detect Chlamydia pneumoniae DNA in cerebral aneursymal sac tissue with two different polymerase chain reaction methods
J. Neurol. Neurosurg. Psychiatry, June 1, 2003; 74(6): 756 - 759.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. M. Boekholdt, W. R.P. Agema, R. J.G. Peters, A. H. Zwinderman, E. E. van der Wall, P. H. Reitsma, J. J.P. Kastelein, and J. W. Jukema
Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events
Circulation, May 20, 2003; 107(19): 2416 - 2421.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. Agmon, B. K. Khandheria, I. Meissner, T. M. Petterson, W. M. O'Fallon, T. J. H. Christianson, D. O. Wiebers, T. F. Smith, J. M. Steckelberg, and A. J. Tajik
Lack of association between Chlamydia pneumoniae seropositivity and aortic atherosclerotic plaques: A Population-Based transesophageal echocardiographic study
J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1482 - 1487.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
M. Cochrane, A. Pospischil, P. Walker, H. Gibbs, and P. Timms
Distribution of Chlamydia pneumoniae DNA in Atherosclerotic Carotid Arteries: Significance for Sampling Procedures
J. Clin. Microbiol., April 1, 2003; 41(4): 1454 - 1457.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. V. Kalayoglu, P. Libby, and G. I. Byrne
Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease
JAMA, December 4, 2002; 288(21): 2724 - 2731.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Prager, Z. Turel, W. S. Speidl, G. Zorn, C. Kaun, A. Niessner, G. Heinze, I. Huk, G. Maurer, K. Huber, et al.
Chlamydia pneumoniae in Carotid Artery Atherosclerosis: A Comparison of Its Presence in Atherosclerotic Plaque, Healthy Vessels, and Circulating Leukocytes From the Same Individuals
Stroke, December 1, 2002; 33(12): 2756 - 2761.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
C. Hermann, K. Graf, A. Groh, E. Straube, and T. Hartung
Comparison of Eleven Commercial Tests for Chlamydia pneumoniae-Specific Immunoglobulin G in Asymptomatic Healthy Individuals
J. Clin. Microbiol., May 1, 2002; 40(5): 1603 - 1609.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. Virok, Z. Kis, L. Karai, L. Intzedy, K. Burian, A. Szabo, B. Ivanyi, E. Gonczol, and M. S. Elkind
Chlamydia pneumoniae in Atherosclerotic Middle Cerebral Artery Editorial Comment
Stroke, September 1, 2001; 32(9): 1973 - 1976.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vink, A.
Right arrow Articles by Pasterkamp, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vink, A.
Right arrow Articles by Pasterkamp, G.
Related Collections
Right arrow Peripheral vascular disease
Right arrow Other etiology
Right arrow Pathophysiology